Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape

Cancer immunotherapy is experiencing a renaissance spearheaded by immune checkpoint inhibitors (ICIs). This has spurred interest in ‘upgrading’ existing immunotherapies that previously experienced only sporadic success, such as dendritic cells (DCs) vaccines. In this review, we discuss the major mol...

Full description

Saved in:
Bibliographic Details
Published in:Trends in immunology 2017-08, Vol.38 (8), p.577-593
Main Authors: Garg, Abhishek D, Coulie, Pierre G, Van den Eynde, Benoit J, Agostinis, Patrizia
Format: Article
Language:English
Subjects:
Allergy and Immunology
Anticancer properties
Antigens, Neoplasm - immunology
Cancer
Cancer immunotherapy
Cancer vaccines
Cancer Vaccines - administration & dosage
Cancer Vaccines - immunology
Chemotherapy, Adjuvant
Combinatorial analysis
CTLA-4 protein
Dendritic cells
Dendritic Cells - immunology
Humans
Immune checkpoint inhibitors
Immunology
Immunotherapy
Immunotherapy - trends
Molecular Targeted Therapy
Neoplasms - immunology
Neoplasms - therapy
PD-1 protein
PD-L1 protein
T cell receptors
Upgrading
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cancer immunotherapy is experiencing a renaissance spearheaded by immune checkpoint inhibitors (ICIs). This has spurred interest in ‘upgrading’ existing immunotherapies that previously experienced only sporadic success, such as dendritic cells (DCs) vaccines. In this review, we discuss the major molecular, immunological, and clinical determinants of existing first- and second-generation DC vaccines. We also outline the future trends for next-generation DC vaccines and describe their major hallmarks and prerequisites necessary for high anticancer efficacy. In addition, using existing data we compare DC vaccines with ICIs targeting CTLA4, PD1, and PD-L1, and argue that in various contexts next-generation DC vaccines are ready to meet some challenges currently confronting ICIs, thereby raising the need to integrate DC vaccines in future combinatorial immunotherapy regimens.
ISSN:1471-4906
1471-4981
DOI:10.1016/j.it.2017.05.006